What is it about?
we found that changes in urinary biomarkers did not correspond to albuminuria levels. This could be because KIM-1 and IL-1β originate from tubular damage and inflammation, whereas albuminuria usually represents glomerular damage, and the primary site of action of SGLT2i is the proximal tubule of the kidney. Therefore, the reduction in the levels of these biomarkers may not be dependent on albuminuria
Featured Image
Why is it important?
SGLT2i therapy can also potentially mitigate kidney injury in patients with CKD and can be initiated even for those who are non-diabetic, with low albuminuria levels. Notably, our study shows that SGLT2 inhibitors can also improve damaged renal mitochondrial function in patients with CKD.
Read the Original
This page is a summary of: Dapagliflozin Reduces Urinary Kidney Injury Biomarkers in Chronic Kidney Disease Irrespective of Albuminuria Level, Clinical Pharmacology & Therapeutics, March 2024, Wiley,
DOI: 10.1002/cpt.3237.
You can read the full text:
Resources
Contributors
The following have contributed to this page
